EU Biotech Hurt By Orphan Drug Legislation Delays - NORD President
Executive Summary
The delay in EU orphan drug legislation caused by European Commission in-fighting about financing is damaging the European biotechnology sector, National Organization of Rare Disorders President Abbey Meyers said at a May 5 workshop in Brussels on rare diseases and orphan drugs.